Antiarrhythmics--from cell to clinic: past, present, and future.
作者信息
Hancox J C, Patel K C, Jones J V
机构信息
Department of Physiology and Cardiovascular Research Laboratories, School of Medical Sciences, University Walk, Bristol BS8 1TD, UK.
出版信息
Heart. 2000 Jul;84(1):14-24. doi: 10.1136/heart.84.1.14.
Abstract
摘要
相似文献
1
Antiarrhythmics--from cell to clinic: past, present, and future.抗心律失常药物——从细胞到临床：过去、现在与未来
Heart. 2000 Jul;84(1):14-24. doi: 10.1136/heart.84.1.14.
2
Antiarrhythmic agents: modulated receptor applications.
Circulation. 1987 Mar;75(3):514-20. doi: 10.1161/01.cir.75.3.514.
3
Antiarrhythmic drugs: electrophysiological basis of their clinical usage.抗心律失常药物：其临床应用的电生理基础
Ann Thorac Surg. 1986 Jan;41(1):106-12. doi: 10.1016/s0003-4975(10)64510-9.
4
Management of ventricular arrhythmias.室性心律失常的管理
Am Fam Physician. 1986 Mar;33(3):236-46.
5
Mechanisms of action of antiarrhythmic drugs: from ion channel blockage to arrhythmia termination.抗心律失常药物的作用机制：从离子通道阻滞到心律失常的终止
Pacing Clin Electrophysiol. 1997 Feb;20(2 Pt 2):432-44. doi: 10.1111/j.1540-8159.1997.tb06202.x.
6
[Electropharmacological basis of antiarrhythmic drugs and treatment of ventricular arrhythmias].
Nihon Yakurigaku Zasshi. 2008 Jun;131(6):446-51. doi: 10.1254/fpj.131.446.
7
Novel targets for cardiac antiarrhythmic drug development.心脏抗心律失常药物研发的新靶点。
Curr Pharm Des. 2005;11(15):1959-74. doi: 10.2174/1381612054021051.
8
Pharmacogenetics and cardiac ion channels.药物遗传学与心脏离子通道
Vascul Pharmacol. 2006 Feb;44(2):90-106. doi: 10.1016/j.vph.2005.07.013. Epub 2005 Dec 15.
9
10
Cellular aspects of antiarrhythmic activity.抗心律失常活性的细胞层面
Verh K Acad Geneeskd Belg. 1975;37(5-6):229-50.
引用本文的文献
1
Critical Volume of Human Myocardium Necessary to Maintain Ventricular Fibrillation.维持心室颤动所需的人类心肌临界体积。
Circ Arrhythm Electrophysiol. 2018 Nov;11(11):e006692. doi: 10.1161/CIRCEP.118.006692.
2
Prophylactic Antiarrhythmic Drug Therapy in Atrial Fibrillation.心房颤动的预防性抗心律失常药物治疗
J Atr Fibrillation. 2013 Feb 12;5(5):636. doi: 10.4022/jafib.636. eCollection 2013 Feb-Mar.
3
Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide.Ic类抗心律失常药物氟卡尼对hERG钾通道的阻断作用的分子基础。
J Mol Cell Cardiol. 2015 Sep;86:42-53. doi: 10.1016/j.yjmcc.2015.06.021. Epub 2015 Jul 6.
4
Pilsicainide.吡司卡尼。
Drugs. 2010 Mar 5;70(4):455-67. doi: 10.2165/11204960-000000000-00000.
5
Failure of plasma brain natriuretic peptide to identify left ventricular systolic dysfunction in the community.
Heart. 2000 Oct;84(4):440-1. doi: 10.1136/heart.84.4.440.
6
Increased formation of F(2)-isoprostanes in patients with severe heart failure.重度心力衰竭患者中F(2)-异前列腺素生成增加。
Heart. 2000 Oct;84(4):439-40. doi: 10.1136/heart.84.4.439.
7
Reduction in Fas/APO-1 plasma concentrations correlates with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with pentoxifylline.
Heart. 2000 Oct;84(4):438-9. doi: 10.1136/heart.84.4.438.
本文引用的文献
1
The physiological disposition and cardiac effects of procaine amide.普鲁卡因酰胺的生理处置及心脏效应。
J Pharmacol Exp Ther. 1951 May;102(1):5-15.
2
Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death.先天性聋哑、伴有Q-T间期延长的功能性心脏病及猝死。
Am Heart J. 1957 Jul;54(1):59-68. doi: 10.1016/0002-8703(57)90079-0.
3
Brugada syndrome.
Lancet. 1999 Aug 7;354(9177):445-6. doi: 10.1016/S0140-6736(99)90032-6.
4
Sensitivity of the slow component of the delayed rectifier potassium current (IKs) to potassium channel blockers: implications for clinical reverse use-dependent effects.延迟整流钾电流（IKs）慢成分对钾通道阻滞剂的敏感性：对临床反向使用依赖性效应的影响。
J Biomed Sci. 1999 Jul-Aug;6(4):251-9. doi: 10.1007/BF02253566.
5
Differential rate and potassium-dependent effects of the class III agents d-sotalol and dofetilide on guinea pig papillary muscle.Ⅲ类药物d-索他洛尔和多非利特对豚鼠乳头肌的差异速率及钾依赖性效应
Cardiovasc Drugs Ther. 1998 Dec;12(6):573-83. doi: 10.1023/a:1007743521932.
6
What should we expect from the next generation of antiarrhythmic drugs?我们对下一代抗心律失常药物有何期待？
J Cardiovasc Electrophysiol. 1999 Feb;10(2):307-17. doi: 10.1111/j.1540-8167.1999.tb00676.x.
7
Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the european society of cardiology.心律失常的遗传和分子基础；对临床管理的影响。欧洲心脏病学会心律失常工作组心律失常分子基础研究组。
Eur Heart J. 1999 Feb;20(3):174-95. doi: 10.1053/euhj.1998.1220.
8
Modulation of HERG potassium channels by extracellular magnesium and quinidine.细胞外镁离子和奎尼丁对HERG钾通道的调节作用
J Cardiovasc Pharmacol. 1999 Feb;33(2):181-5. doi: 10.1097/00005344-199902000-00002.
9
The role of sarcolemmal Ca2+-ATPase in the regulation of resting calcium concentration in rat ventricular myocytes.肌膜钙ATP酶在调节大鼠心室肌细胞静息钙浓度中的作用。
J Physiol. 1999 Feb 15;515 ( Pt 1)(Pt 1):109-18. doi: 10.1111/j.1469-7793.1999.109ad.x.
10
Clinical pharmacokinetics of mibefradil.米贝拉地尔的临床药代动力学
Clin Pharmacokinet. 1998 Dec;35(6):405-23. doi: 10.2165/00003088-199835060-00001.
Zotero 插件